Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01874015|
Recruitment Status : Recruiting
First Posted : June 10, 2013
Last Update Posted : April 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease||Biological: mesenchymal cell transplantation Biological: mesenchymal cell and fibroblast injection||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Transplantation of Bone Marrow Mesenchymal Stem Cell in Moderate to Severe Fistulizing Crohn's Disease|
|Actual Study Start Date :||February 2013|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||February 2018|
Active Comparator: mesenchymal cell and fibroblast transplantaion
The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
Biological: mesenchymal cell and fibroblast injection
Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
Active Comparator: mesenchymal cell transplantaion
The patients with Crohn's disease who underwent mesenchymal cell transplantation.
Biological: mesenchymal cell transplantation
Mesenchymal cell transplantation in patients with Crohn's disease.
- fistula closure [ Time Frame: 4months ]Evaluation the fistula closure after mesenchymal cell transplantation in patients with crohn's disease.
- CDAI [ Time Frame: 4months ]Evaluation the decrease of CDAI after mesenchymal cell transplantation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01874015
|Contact: Nasser Aghdami, MD,PhD||+9823562000 ext email@example.com|
|Contact: Leila Arab, MD||+9823562000 ext 414||Leara91@gmail.com|
|Iran, Islamic Republic of|
|Tehran, Iran, Islamic Republic of|
|Contact: Nasser Aghdami, MD,PhD|
|Principal Investigator: Massoud Vosough, MD,PhD|
|Sub-Investigator: vagihe azimian, MSc|
|Study Chair:||Hamid Gourabi, PhD||Head of Royan Institute|
|Study Director:||Nasser Aghdami, MD,PhD||Head of Royan department of degenerative medicine,Head of Royan celltherapy center|
|Study Director:||Mahdi Mohammad Nejhad, MD||TUMS DDRI|